Skip to main content

Table 1 Characteristics of the patients with bladder cancer

From: Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study

 

HIVEC+TUR (n = 128)

HIVEC (n = 37)

P

Age (years)

50.7 ± 1.9 (37–66)

51.6 ± 2.3 (39–66)

0.07

Sex, n (%)

 Male

86 (67.2)

22 (59.5)

0.09

 Female

42 (32.8)

15 (40.5)

0.07

Disease course (days)

11.4 ± 1.3

11.3 ± 1.6

0.07

Tumor location, n (%)

 Side wall

35 (27.3)

1 (2.7)

0.06

 Posterior wall

27 (21.1)

2 (5.4)

0.08

 Top area

19 (14.8)

1 (2.7)

0.08

 Triangle area

10 (7.8)

17 (45.9)

0.06

  ≥ two tumors

37 (28.9)

16 (43.2)

0.07

Tumor size, n (%)

  ≥ 0.5 cm

66 (51.6)

28 (75.6)

0.07

  < 0.5 cm

62 (48.4)

9 (24.4)

0.09

Tumor stage, n (%)

 Tis

13 (10.2)

0

0.06

 T1

73 (57.0)

9 (24.3)

0.06

 T2

42 (32.8)

28 (75.7)

0.08

Tumor differentiation, n (%)

 G1

41 (32.0)

11 (29.7)

0.08

 G2

54 (42.2)

14 (37.8)

0.08

 G3

33 (25.8)

12 (32.4)

0.75

  1. HIVEC: bladder intracavitary hyperthermic perfusion chemotherapy